cizzle biotech develops a new lung cancer test
Cizzle Biotechnology PLC is a cancer diagnostics spin-out from the University of York
Cizzle Biotech was initially funded by Yorkshire Cancer Research, White Rose Technology Seed Corn Fund, Finance Yorkshire Seedcorn LLP and Viking Members, who with management, invested in the project to support the development of a prototype blood test.
Cizzle Biotech has gained patent protection for its core technology and has developed a laboratory test, which has been used to validate the use of the CIZ1 B biomarker to detect lung cancer.
the CIZ1 B biomarker
CIZ1 Clinical Validation Success
Cizzle Biotech has a laboratory test, which has been used to validate the use of CIZ1 B to detect lung cancer and a proof-of-concept prototype test which is compatible with potential use within a hospital laboratory setting
Mammalian Cell Cycle Research Group
The test is underpinned by 15 years of grant funded basic research into CIZ1 form and function, and its relationship with cancer. This has shown that CIZ1 is part of the nuclear structure that controls gene expression. A variant form, CIZ1 B is produced by lung cancer cells and can be exploited to detect lung cancer.